Meridian Signs Final Contract and Receives Initial Purchase Order for the Exclusive Distribution of Its Lapex-2000 LipoLaser in Japan

The agreement provides for the marketing and distribution of Meridian's Lapex-2000 LipoLaser. The Lapex-2000 LipoLaser will be exclusively marketed and sold by Leichel under the brand name of Lipo Shape. Their exclusive distributorship for the Lipo Shape is based on a minimum order volume equal to sales of US$6 million for the initial 12-month period of the agreement.

Meridian has accepted a US$500,000 purchase order, along with a 50% deposit, for the initial order placed under the signed contract. Delivery is expected within the current quarter.

More About the Lapex 2000 LipoLaser:

The Lapex 2000 LipoLaser was designed to target the medical and aesthetic market, specifically to address body shaping/contouring, spot fat reduction, and reduction in the appearance of cellulite. The Lapex 2000 LipoLaser's non-invasive treatment is considered one of the most innovative methods to treat those stubborn areas of fat that have not responded to diet and exercise. The demand for this type of treatment is expected to grow rapidly, not only in the plastic surgery profession but in any clinical setting such as spas and wellness centers that treat localized body fat deposits which may not have responded to diet and exercise.

Light-based treatments are now the mainstays of medical aesthetic practices. These treatments earned more than $8 billion for practitioners and almost $550 million for equipment manufacturers. By 2009, this is expected to grow to over 84 million treatments annually earning practitioners $13.9 billion and manufacturers nearly $1 billion.

More About: Meridian

Meridian is an established leader in the research/development, manufacturing and sales of integrative medical equipment. The Company sells its products and equipment to a wide range of customers in the global health care industry. The Company presently holds a total of 18 worldwide patents on its technology, and has received FDA approval, as well as other international regulatory approvals, for many of its products.

On Behalf of the Board of Directors, Hyeon Seong Myeong President

This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the Company.

Website: www.MeridianMedical.ca